BioCentury
ARTICLE | Clinical News

Maribavir: Interim Phase II data

May 6, 2013 7:00 AM UTC

ViroPharma disclosed on its 1Q13 earnings call that interim data from 36 patients with asymptomatic CMV infection in a European Phase II trial showed that twice-daily oral maribavir led to undetectable plasma CMV DNA in 93% of patients (n=28) vs. 63% of patients receiving Valcyte valganciclovir (n=8). One patient receiving maribavir did not clear virus while on treatment and the other was withdrawn from treatment for non-biologic reasons before clearing virus. Three patients in the Valcyte arm were withdrawn from treatment for non-biologic reasons. Maribavir was safe with taste disturbance reported as the most common adverse event. The trial is slated to enroll 160 patients who received hematopoietic stem cell or solid organ transplants and have demonstrated CMV viremia but do not have CMV organ disease to receive twice-daily 400, 800 or 1,200 mg maribavir or Valcyte for up to 12 weeks. ...